Faeth Therapeutics, Inc. (FTH) Current Ratio
- Current ratio · latest quarter: Value 19.69×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 19.69× | Current assets / current liabilities. $188.66M ÷ $9.58M ≈ 19.69× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 188.66M USD | Assets, Current |
| Current obligations | 9.58M USD | Liabilities, Current |
| Cash and equivalents | 26.90M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 159.54M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.15M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $188.66M | $9.58M | $26.90M | $159.54M | (m) | (m) | $2.15M | (m) | 19.69× |
| 2026-03-31 | $204.23M | $14.19M | $152.32M | $50.47M | (m) | (m) | $3.42M | (m) | 14.39× |
| 2025-12-31 | $21.51M | $4.25M | $8.67M | $12.52M | (m) | (m) | $689.00K | (m) | 5.06× |
| 2025-09-30 | $25.79M | $4.44M | $10.56M | $14.48M | (m) | (m) | $306.00K | (m) | 5.81× |
| 2025-06-30 | $29.57M | $3.87M | $12.56M | $16.07M | (m) | (m) | $351.00K | (m) | 7.64× |
| 2025-03-31 | $35.68M | $5.23M | $9.88M | $24.45M | (m) | (m) | $361.00K | (m) | 6.82× |
| 2024-12-31 | $41.93M | $5.45M | $9.99M | $31.34M | (m) | (m) | $244.00K | (m) | 7.70× |
| 2024-09-30 | $48.10M | $5.44M | $19.13M | $27.87M | (m) | (m) | (m) | (m) | 8.84× |
| 2024-06-30 | $53.94M | $4.95M | $11.89M | $40.40M | (m) | (m) | (m) | (m) | 10.90× |
| 2024-03-31 | $60.23M | $4.99M | $10.96M | $47.13M | (m) | (m) | (m) | (m) | 12.07× |
| 2023-12-31 | $67.25M | $5.64M | $13.01M | $52.75M | (m) | (m) | $573.00K | (m) | 11.92× |
| 2023-09-30 | $73.84M | $6.23M | $11.34M | $60.67M | (m) | (m) | (m) | (m) | 11.86× |
| 2023-06-30 | $81.07M | $5.36M | $10.23M | $68.61M | (m) | (m) | (m) | (m) | 15.13× |
| 2023-03-31 | $98.61M | $7.58M | $8.11M | $87.40M | (m) | (m) | (m) | (m) | 13.00× |
| 2022-12-31 | $108.59M | $9.07M | $17.80M | $89.32M | (m) | (m) | (m) | (m) | 11.98× |
| 2022-09-30 | $118.48M | $8.49M | $11.45M | $105.11M | (m) | (m) | (m) | (m) | 13.95× |
| 2022-06-30 | $127.49M | $5.43M | $9.90M | $113.81M | (m) | (m) | (m) | (m) | 23.46× |
| 2022-03-31 | $138.98M | $7.61M | $8.72M | $127.50M | (m) | (m) | (m) | (m) | 18.27× |
| 2021-12-31 | $148.54M | $4.89M | $7.16M | $140.46M | (m) | (m) | (m) | (m) | 30.38× |
| 2021-09-30 | $158.16M | $5.26M | $9.53M | $147.13M | (m) | (m) | (m) | (m) | 30.05× |
| 2021-06-30 | $165.61M | $3.92M | $15.60M | $146.90M | (m) | (m) | (m) | (m) | 42.22× |
| 2021-03-31 | $172.78M | $2.48M | $169.42M | (m) | (m) | (m) | (m) | (m) | 69.81× |
| 2020-12-31 | $20.08M | $4.83M | $16.60M | (m) | (m) | (m) | (m) | (m) | 4.16× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |